The results showed that patients with high SLNCR1 expression may have a higher risk of P53 mutation (p = 0.0335) and lymph node metastasis (p = 0.0377) than patients with low expression (Table 1). This evidence concerns the gene TP53 and metastatic malignant neoplasm in the lymph nodes.